A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting now · Phase 3

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

Key facts

Study ID

NCT07518186

Run by

Janssen Research & Development, LLC

People needed

700

Starts

2026-05-31

Expected to finish

2032-12-08

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory
• Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide
• Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication
• Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment

You may not qualify if…

• Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
• Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients
• Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM
• Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required

Where it is running

• Mayo Clinic 1 — Phoenix, Arizona, United States (enrolling)
• Highlands Oncology Group — Springdale, Arkansas, United States (enrolling)
• Beverly Hills Cancer Center Clinical Research Advisors LLC — Beverly Hills, California, United States (enrolling)
• Valkyrie Clinical Trials — Los Angeles, California, United States (enrolling)
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States (enrolling)
• Memorial Cancer Institute — Pembroke Pines, Florida, United States (enrolling)
• Emory University — Atlanta, Georgia, United States (enrolling)
• Franciscan Health — Indianapolis, Indiana, United States (enrolling)
• Norton Cancer Institute — Louisville, Kentucky, United States (enrolling)
• LSU Health Feist Weiller Cancer Center — Shreveport, Louisiana, United States (enrolling)
• Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
• University Of Minnesota Medical Center — Minneapolis, Minnesota, United States (enrolling)
• Mayo Clinic — Rochester, Minnesota, United States (enrolling)
• Nebraska Cancer Specialists — Omaha, Nebraska, United States (enrolling)
• Astera Cancer Care — East Brunswick, New Jersey, United States (enrolling)
• Christus St. Vincent Regional Cancer Center — Santa Fe, New Mexico, United States (enrolling)
• New York Oncology Hematology — Albany, New York, United States (enrolling)
• Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York, United States (enrolling)
• NYU Langone Health Manhattan — New York, New York, United States (enrolling)
• New York Cancer and Blood Specialists — Shirley, New York, United States (enrolling)
• Gabrail Cancer Center — Canton, Ohio, United States (enrolling)
• The Christ Hospital — Cincinnati, Ohio, United States (enrolling)
• Bon Secours Saint Francis Cancer Center — Greenville, South Carolina, United States (enrolling)
• Joe Arrington Cancer Research Treatment Center — Lubbock, Texas, United States (enrolling)
• Alabama Oncology — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.